CJC-1295 + Ipamorelin
5mg each · 99%+ Purity
HPLC Tested
99%+ Purity
About Our Testing
Every batch is tested by our manufacturer using HPLC analysis. Per-batch third-party testing adds significant cost and delays that would be passed to customers.
Fast Shipping
Same-day dispatch
Description
CJC-1295 + Ipamorelin stack (5mg each) at 99%+ purity. Synergistic GH release for muscle growth and anti-aging research.
Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.
Research & Science
Evidence-based information about this compound
Chemical Properties
Also known as:
CJC-1295/Ipamorelin Blend, Mod GRF + IPAM, GHRH + GHRP Stack
The CJC-1295 + Ipamorelin combination pairs two complementary peptides that work through different but synergistic pathways to enhance growth hormone release. This stack combines a GHRH analog (CJC-1295) with a selective GHRP (Ipamorelin).
CJC-1295 (Modified GRF 1-29) stimulates growth hormone through the GHRH receptor, while Ipamorelin works through the ghrelin/GHS receptor. Together, they activate both primary pathways for growth hormone release from the pituitary.
This combination has become one of the most popular pairings in growth hormone research due to the synergistic amplification of GH release observed when both pathways are activated simultaneously.
The CJC-1295 + Ipamorelin combination works through dual pathway activation:
- GHRH Pathway: CJC-1295 activates the GHRH receptor to stimulate GH synthesis and release.
- Ghrelin Pathway: Ipamorelin activates the GHS receptor for additional GH release.
- Synergistic Effect: Simultaneous activation of both pathways produces greater GH release than either alone.
- Amplified Pulses: Results in larger amplitude growth hormone pulses while maintaining natural patterns.
- Selective Action: Ipamorelin's selectivity helps maintain a cleaner hormonal profile.
Research supports the synergistic effects of combining GHRH and GHRP compounds:
- Amplified Release: Studies show GH release from the combination exceeds the sum of individual compounds.
- Dual Pathway: Activating both receptor systems provides more robust stimulation of GH secretion.
- Maintained Selectivity: The combination retains Ipamorelin's selective profile without significant cortisol or prolactin effects.
- Enhanced IGF-1: Greater GH release translates to increased IGF-1 production.
This synergistic approach represents an optimized strategy for growth hormone research.
Sources:
This information is provided for educational purposes only and is based on published scientific research. This product is intended for research use only.
